The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Issue 3 (5th January 2016)

• Record Type: Journal Article
• Authors: Fisher, Oliver M; Lord, Sarah J; Falkenback, Dan; Clemons, Nicholas J; Eslick, Guy D; Lord, Reginald V
• Is Part Of: Gut. Volume 66:Issue 3(2017)
• Page Start: 399
• Page End: 410
• Publication Date: 2016-01-05
• Subjects: OESOPHAGEAL CANCER -- META-ANALYSIS; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2015-310888
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: To clarify the prognostic role of tumour protein 53 (TP53) mutations in patients with oesophageal adenocarcinoma (OAC) as there is a need for biomarkers that assist in guiding management for patients with OAC. Design: A systematic review was conducted using MEDLINE, Embase, PubMed and Current Contents Connect to identify studies published between January 1990 and February 2015 of oesophageal cancer populations (with OAC diagnoses >50% of cases) that measured tumoural TP53 status and reported hazard ratios (HR), or adequate data for estimation of HR for survival for TP53-defined subgroups. Risk of bias for HR estimates was assessed using prespecified criteria for the appraisal of relevant domains as defined by the Cochrane Prognosis Methods Group including adherence to Grading of Recommendations, Assessment, Development and Evaluation and REporting recommendations for tumor MARKer prognostic studies guidelines, as well as assay method used (direct TP53 mutation assessment vs immunohistochemistry) and adjustment for standard prognostic factors. A pooled HR and 95% CI were calculated using a random-effects model. Results: Sixteen eligible studies (11 with OAC only and 5 mixed histology cohorts) including 888 patients were identified. TP53 mutations were associated with reduced survival (HR 1.48, 95% CI 1.16 to 1.90, I 2 =33%). A greater prognostic effect was observed in a sensitivity analysis of those studies that reported survival for OAC-only cohorts and were assessed at low risk of bias (HR 2.11, 95% CI 1.35 to 3.31, I 2 =0%). Conclusions: Patients with OAC and TP53 gene mutations have reduced overall survival compared with patients without these mutations, and this effect is independent of tumour stage.